The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

Multiple Sclerosis

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study

PLoS One.

Izquierdo G, Damas F, Páramo MD, Ruiz-Peña JL, Navarro G

doi: 10.1371/

Multiple Sclerosis

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Lancet Neurol.

Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I

doi: 10.1016/

Multiple Sclerosis

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies

Eur J Neurol.

Havrdova E, Giovannoni G, Gold R, Fox RJ, Kappos L, Phillips JT, Okwuokenye M, Marantz JL

doi: 10.1111/ene.13272.

Multiple Sclerosis

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

Mult Scler.

Van Wijmeersch B, Singer BA, Boster A, Broadley S, Fernández Ó, Freedman MS, Izquierdo G, Lycke J, Pozzilli C, Sharrack B, Steingo B, Wiendl H, Wray S, Ziemssen T, Chung L, Margolin DH, Thangavelu K, Vermersch P

doi: 10.1177/1352458519881759.

Multiple Sclerosis

Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis

Mult Scler.

Lorscheider J, Benkert P, Lienert C, Hänni P, Derfuss T, Kuhle J, Kappos L, Yaldizli Ö

doi: 10.1177/1352458518768433.

RECOMMENDED

Multiple Sclerosis

Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study

Ther Adv Neurol Disord.

Kallmann BA, Tiel-Wilck K, Kullmann JS, Engelmann U, Chan A

doi: 10.1177/

Multiple Sclerosis

BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS

Mult Scler

Cohen M, Mondot L, Bucciarelli F, Pignolet B, Laplaud DA, Wiertlewski S, Brochet B, Ruet A, Defer G, Derache N, Vermersch P, Zephir H, Debouverie M, Mathey G, Berger E, Cappé C, Labauge P, Carra C, De Seze J, Bigaut K, Brassat D, Lebrun-Frenay C

doi: 10.1177/1352458520969145

Related content

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis

Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study

BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS